Impact News +++ Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired... (GlobeNewswire EN) +++ RHYTHM PHARMACEUTICALS Aktie -4,94%

RHYTHM PHARMACEUTICALS Aktie

>RHYTHM PHARMA Aktienkurs

77 EUR +0.7% (TradegateBSX)

Ask: 79.5 EUR / 37 Stück

Bid: 76 EUR / 39 Stück

Tagesumsatz: 391 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>RHYTHM PHARMA Performance

1 Woche: -1,3%

1 Monat: +4,1%

3 Monate: -3,5%

6 Monate: -21,5%

1 Jahr: +40,4%

laufendes Jahr: -19,9%

>RHYTHM PHARMACEUTICALS Aktie

Name:

RHYTHM PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US76243J1051 / A2H5A0

Symbol/ Ticker:

1RV (Frankfurt) / RYTM (NASDAQ)

Kürzel:

FRA:1RV, ETR:1RV, 1RV:GR, NASDAQ:RYTM

Index:

Webseite:

https://www.rhythmtx.com/

Profil:

Rhythm Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases, particularly those involving hyperphagia and severe obesity. Its lead product, IMCIVREE ..
>Volltext..

Marktkapitalisierung:

5240.76 Mio. EUR

Unternehmenswert:

5142.36 Mio. EUR

Umsatz:

187.74 Mio. EUR

EBITDA:

-169.58 Mio. EUR

Nettogewinn:

-175.21 Mio. EUR

Gewinn je Aktie:

-2.71 EUR

Schulden:

196.25 Mio. EUR

Liquide Mittel:

53.72 Mio. EUR

Operativer Cashflow:

-103.31 Mio. EUR

Bargeldquote:

3.3

Umsatzwachstum:

48.58%

Gewinnwachstum:

-12.5%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 369.117 Euro.

Suchwörter:

RHYTHM PHARMACEUTICALS, RHYTHM PHARMA, RHYTHM PHARMACEUTICAL

Letzte Datenerhebung:

15.06.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 68.59 Mio. St.

Frei handelbar: 96.84%

Leerverk. Aktien: 11.54%

Rückkaufquote: -3.99%

Mitarbeiter: 414

Umsatz/Mitarb.: 0.4 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 58.89%

Bewertung:

KGV: -

KGV lG: -

KUV: 26.63

KBV: 48.26

PEG-Ratio: -2.37

EV/EBITDA: -

Rentabilität:

Bruttomarge: 89.25%

Gewinnmarge: -93.33%

Operative Marge: -90.89%

Managementeffizenz:

Gesamtkaprendite: -48.9%

Eigenkaprendite: -285.76%

>Peer Group

Gesundheit, Nahrungsergänzungsmittel & Wellnessprodukte, Stoffwechselerkrankungen (Diabetes/ Adipositas), Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>RHYTHM PHARMA Chart & Kurs - NASDAQ

>RHYTHM PHARMA News

15.06.26 - 22:03	Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026 (GlobeNewswire EN)
	-- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years -- -- Bivamelagon therapy achieved progressive reductions in BMI and hunger measures in patients (N=26) with acquired HO at one year --...

13.06.26 - 14:03	Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 (GlobeNewswire EN)
	-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures -- -- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --...

12.06.26 - 22:03

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome (GlobeNewswire EN)

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Saturday, June 13 at 9:00 a.m. ET/8:00 a.m. CT to discuss interim six-month results from the Company's Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS)....

29.05.26 - 14:03

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026 (GlobeNewswire EN)

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that seven presentations, including four late-breaking abstracts, have been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2026) taking place June 13-16, 2026 in Chicago....

26.05.26 - 14:03

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences (GlobeNewswire EN)

BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, and Hunter Smith, Chief Financial Officer, will participate in fireside chats at two upcoming conferences....

20.05.26 - 00:01	Insiderhandel: Corporate Controller & CAO verkauft Aktien von Rhythm Pharmaceuticals im Wert von 428131 USD (Insiderkauf)
	German, Christopher Paul - Vorstand - Tag der Transaktion: 2026-05-15...

12.05.26 - 14:03	Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology (GlobeNewswire EN)
	– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France –...

06.05.26 - 20:09	Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results (Benzinga)
	Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan. Latest Ratings for RYTM DateFirmActionFromTo Mar 2022Canaccord GenuityMaintainsBuy Mar 2022NeedhamMaintainsBuy Feb 2022NeedhamMaintainsBuy View More Analyst Ratings for RYTM View the Latest Analyst Ratings Importance Rank: 1 read more...

06.05.26 - 14:03

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference (GlobeNewswire EN)

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Bank of America Global Healthcare Conference on Wednesday, May 13 at 3:00 p.m. PT in Las Vegas....

06.05.26 - 02:12	Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday (Fool)
	It released an encouraging quarterly earnings report and business update before market open....

05.05.26 - 16:00	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
	Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +3.04% and +5.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?...

05.05.26 - 15:18	Rhythm Pharmaceuticals übertrifft Umsatzprognose für Q1 2026 dank starkem Auslandsgeschäft (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

05.05.26 - 13:30	Rhythm Pharmaceuticals reports Q1 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

01.05.26 - 17:36	Rhythm Pharmaceuticals: Aktie steigt nach EU-Zulassung für Adipositas-Medikament (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

01.05.26 - 12:57	Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity (GlobeNewswire EN)
	-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment --...

28.04.26 - 17:31	Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for (Zacks)
	Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

09.04.26 - 14:03

Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026 (GlobeNewswire EN)

BOSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8 a.m. ET on Tuesday, May 5, 2026 to report its first quarter 2026 financial results and provide a corporate update....

03.04.26 - 15:03

Rhythm Pharmaceuticals Announces Changes to Board of Directors (GlobeNewswire EN)

-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced changes to its Board of Directors, including the appointment of Kim Popovits and the departure of Ed Mathers....

01.04.26 - 16:00	Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength? (Zacks)
	Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term....

26.03.26 - 15:06	Rhythm Pharma wins EU backing to expand Imcivree label (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Schlagworte sind Kommandos der Dummheit. - Hans Lohberger

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram